КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ И ПРОГНОСТИЧЕСКАЯ РОЛЬ АНТИТЕЛ К РЕЦЕПТОРУ ТТГ У ДЕТЕЙ С БОЛЕЗНЬЮ ГРЕЙВСА
Аннотация
Список литературы
1. раверман Л.И. Болезни щитовидной железы. М., 2001.
2. Бузиашвили И.И., Фадеев В.В., Мельниченко Г.А. Лечение токсического зоба // Врач. 2005. № 23. С. 32-35.
3. Гланц С. Медикобиологическая статистика. М.: Практика, 1999.
4. Петунина Н.А. Прогностические факторы и оптимизация методов лечения диффузного токсического зоба: Дис.... докт. мед. наук. М., 2005.
5. Свириденко Н.Ю., Крюкова И.В., Кеда Ю.М. и др. Клиническое значение иммунологических маркеров диффузного токсического зоба // Проблемы эндокринологии. 1998. № 1. С. 21-24.
6. Фадеев В.В., Бузиашвили И.И., Абрамова Н.А., Мельниченко Г.А Отдаленные результаты консервативного и хирургического лечения токсического зоба // Проблемы эндокриноло гии. 2004. № 6. С. 3-9.
7. Adams D., Purves H. Abnormal responses in the assay of thyrotropins. Ргос. Umv. Otаgо. SA. Меё., 1956. P. 34-12.
8. Braveman L., Utiger R.D. et аl. The thyroid: fundamental and clinical text. Philadelphia. 2000. P. 415.
9. Brunn J., Block U., Ruf G. et al. Volumetrie der schilddri.isenlappen mittels real-time sonographie // Dtsch. Med. Wochenschr. 1981. V. 106. P. 1338-1340.
10. Chiovato L., Vitti P., Bendinelli G. et al. Detection of antibodies blocking thyrotropin effect using Chinese hamster ovary ceHs transfected with the cloned hyman TSH receptor // J. Endjcr. Invest. 1994. V. 17. P. 809-816.
11. Davies T.P., Roti E., Braverman L.E. et al. Thyroid controversy-stimulating antibodies // J. Clin. Endocrinol. Metab. 1998. V. 83. P. 3777-3785.
12. Dotsch J., Rascher W., Dorr H. Graves disease in childhood: a review of the options for diagnosis and treatment // Pediatr. Drugs. 2003. V. 5. P. 95-102.
13. Endo K., Kasagi K., Konishi J. et al. Detection and properties of TSH-binding inhibitor immunnoglobulins in patients with Graves’ disease and Hashimoto’s thyroiditis // Clin. Endocrinol. Metab. 1978. V. 46. P. 734-739.
14. Foley T.P., White C., New B.A. Juvenile Graves disease: usefulness and limitations of thyrotropin receptor antibody determinations // J. Pediatr. 1987. V. 110. P. 378-386.
15. Glaser N.S., Styne D.M. Predictors of early remission of hyperthyroidism in children // J. Clin. Endocrinol. Metab. 1997. N 82. P. 1719-26.
16. Gupta M.K. Thyrotropin receptor antibodies: advances and importance of detection techniques in thyroid diseases // J. Clin. Biochem. 1992. V. 25. P. 193-199.
17. Hamburger J.I. Management of hyperthyroidism in children and adolescents // J. Clin. Endocrinol. Metab. 1985. V. 60. P. 1019-24.
18. Kashiwai T., Hidaka Y., Takano T. et al. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves’ disease // Endocrine J. 2003. V. 50. P. 45-49.
19. Kraiem Z., Cho B., Sadeh O. et al. The IgG subclass distributions of TSH receptor bloking antibodies in primary hypothyroidism // J. Clin. Endocrinology. 1992. V. 37. P. 135-140.
20. Lavard L, Ranlov R., Perrild H. et al. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study // Eur. J. Endocrinol. 1994. V. 130. P. 565-568.
21. Lucas A., Salinas I., Rius F. et al. Medical therapy of Graves’ disease: does thyroxine prevent recurence of hyperthyroidism? // J. Clin. Endocrinol. Metab. 1997. V. 82. P. 2410-2413.
22. Matsuura N., Yamada Y., Nohara Y. et al. Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunnoglobulins // N. Engl. J. Med. 1980. V. 303. P. 738-41.
23. Michelangeli V.P., Munro D.S., Poon C.W. et al. Measurement of thyroid stimulating immunoglobulins in a new cell-lines transfected with a functional human TSH receptor (Jpa9 cells), compared with an assay using FRTL-5 cells // J. Clin. Endocrinol. 1994. V. 40. P. 645-652.
24. Morgenthaler N.G., Pampel I., Aust 0. et al. Application of a bioassay with cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor // Horm. Metab. Res. 1998. V. 30. P. 162-168.
25. Mussa G., Corrias A., Silvestro L. et al. Factors at onset predictive of lasting remission in pediatric patients with Graves’ disease followed for at least three years // J. Pediatr. Endocrinol. Metabol. 1999. V. 12. P. 537-541.
26. Nagayama Y., Wadsworth H.L., Russo D. et al. Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors // J. Clin. Invest. 1991. V. 88. P. 336-340.
27. Orgiazzi J. Anti-TSH receptor antibodies in clinical practice // J. Endocrinol. Metab. Clin. North. Am. 2000. N 229. P. 339-355.
28. Pastan I., Roth J., Macchia V.Binding of hormone to tissue: the first step in polypeptide hormone action // Proc. Natl. Acad. Sci. USA. 1966. V. 56. P. 1802-1809.
29. Rapoport B., Greenspan F.S., Filetti S. et al. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin // J. Clin. Endocrinol. Metab. 1984. V. 58. P. 332-338.
30. Rees Smith B., McLachlan S.M., Furmaniak J. Autoantibodies to the thyrotropin receptor // Endocr. Rev. 1988. V. 9. P. 106-121.
31. Rittmaster R.S., Zwicker H, Abbott E.C. et al. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves’ disease // J. Clin. Endocrinol. Metab. 1996. V. 181. P. 3283-3288.
32. Roti E., Davies T.F., Braveerman E., DeGroot J. Thyroid controversy: stimulating antibodies // J. Clin. Endocrinol. Metab. 1998. V. 83. P. 3777-3785.
33. Schott M., Morgenthaler N.G., Fritzen R. et al. Levels of autoantibodies against human TSH receptor predict relaps of hyperthyroidism in Graves’ disease // Horm. Metab. Res. 2004. V. 36. P. 92-96.
34. Shibayama K., Ohyama Y., Yokota Y. et al. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunnoglobulins in children with Graves’ disease // Endocrine J. 2005. V. 52. P. 505-510.
35. Smith B.R., HaH R. Binding of thyroid stimulators to thyroid membranes // FEBS Lett. 1974. V. 42. P. 301-304.
36. Takasu N., Oshiro C., Akamine H. et al. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects // Endocrinol. Invest. 1997. V. 20. P. 452-461.
37. Takasu N., Yamashiro K. et al. Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment // Thyroid. 2000. V. 10. P. 891-986.
38. Vitti P., Velente V., Ambesi-Impiombato F.S. et al. Graves’ IgG stimulation of continuously cultured rat thyroid cells: a sensitive and potentially useful clinical assay // J. Endocrin. Invest. 1982. V. 5. P. 179-182.
39. Volpe R. Thyroid function and disease. In.: Burrow G.N. et al. (Ed.). Philadelphia., 1989. P. 191-207.
40. Weetman A.P., Yateman M.E., Ealey P.A. et al. Thyroid-stimulating antibody activity between different immunoglobu1in G subc1asses // J. Clin. Invest. 1990. V. 86. P. 723-727.
41. World Health Organization. United Nations Children’s Fund. ICCIDD. Assessment of iodine deficiency disorders and monitoring their elimination. A guide for program managers. Geneva: WHO, 2001.
42. Zimmermann-Belsing T., Nygaard B., Rasmussen A.K. et al. Use of the 2-nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves’ disease // Eur. J. Endocrinology. 2002. V. 146. P. 173-177.
Для цитирования:
Smirnova G.E., Prokofiev S.A., Zvereva J.S., Beslepkina O.B., Peterkova V.A. КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ И ПРОГНОСТИЧЕСКАЯ РОЛЬ АНТИТЕЛ К РЕЦЕПТОРУ ТТГ У ДЕТЕЙ С БОЛЕЗНЬЮ ГРЕЙВСА. Клиническая и экспериментальная тиреоидология. 2006;2(3):44-50. https://doi.org/10.14341/ket20062344-50
For citation:
., ., ., ., . Clinical and Prognostic Value of Anti-thyrotropin Antibodies in Children with Graves’ Disease. Clinical and experimental thyroidology. 2006;2(3):44-50. (In Russ.) https://doi.org/10.14341/ket20062344-50